206 related articles for article (PubMed ID: 18931592)
1. [Secondary myelodysplasia and leukemia following carboplatin and paclitaxel-containing chemotherapy for ovarian cancer].
Abe A; Ikawa H; Muguruma H; Maeda Y
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1795-8. PubMed ID: 18931592
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: a prospective EEG mapping study in 28 patients.
Mayerhofer K; Bodner K; Saletu B; Bodner-Adler B; Anderer P; Hefler L; Schindl M; Kaider A; Leodolter S; Kainz C
Anticancer Res; 2001; 21(1B):803-8. PubMed ID: 11299847
[TBL] [Abstract][Full Text] [Related]
3. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
4. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
5. Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review.
Yeasmin S; Nakayama K; Ishibashi M; Oride A; Katagiri A; Purwana IN; Iida K; Nakayama N; Ishikura H; Miyazaki K
Int J Gynecol Cancer; 2008; 18(6):1371-6. PubMed ID: 18217963
[TBL] [Abstract][Full Text] [Related]
6. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
8. A case of pure-type ovarian squamous cell carcinoma for which combination chemotherapy consisting of paclitaxel and carboplatin was not effective.
Todo Y; Minobe S; Sasaki M; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Apr; 97(1):223-7. PubMed ID: 15790463
[TBL] [Abstract][Full Text] [Related]
9. [Combination chemotherapy with paclitaxel and carboplatin (TC therapy) for endometrial cancer].
Misawa A; Nagao M; Kushimoto T; Yasuda M
Gan To Kagaku Ryoho; 2008 Nov; 35(11):1901-5. PubMed ID: 19011339
[TBL] [Abstract][Full Text] [Related]
10. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
Gréen H; Söderkvist P; Rosenberg P; Horvath G; Peterson C
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):854-9. PubMed ID: 16467099
[TBL] [Abstract][Full Text] [Related]
11. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
12. Secondary myelodysplasia and acute leukemia following carboplatin-containing combination chemotherapy for ovarian cancer.
Colon-Otero G; Malkasian GD; Edmonson JH
J Natl Cancer Inst; 1993 Nov; 85(22):1858-60. PubMed ID: 8230267
[No Abstract] [Full Text] [Related]
13. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors.
Takeyama K; Seto M; Uike N; Hamajima N; Ino T; Mikuni C; Kobayashi T; Maruta A; Muto Y; Maseki N; Sakamaki H; Saitoh H; Shimoyama M; Ueda R
Int J Hematol; 2000 Feb; 71(2):144-52. PubMed ID: 10745624
[TBL] [Abstract][Full Text] [Related]
14. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
Neubauer H; Stefanova M; Solomayer E; Meisner C; Zwirner M; Wallwiener D; Fehm T
Anticancer Res; 2008; 28(2A):949-55. PubMed ID: 18507041
[TBL] [Abstract][Full Text] [Related]
15. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
17. Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy.
Doi D; Boh Y; Konishi H; Asakura H; Takeshita T
Arch Gynecol Obstet; 2009 Oct; 280(4):633-6. PubMed ID: 19205713
[TBL] [Abstract][Full Text] [Related]
18. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
19. [Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer].
Shimura K; Shimazaki C; Okano A; Hatsuse M; Okamoto A; Takahashi R; Hirai H; Sumikuma T; Ashihara E; Inaba T; Fujita N; Yasuda J; Nakagawa M
Rinsho Ketsueki; 2001 Feb; 42(2):99-103. PubMed ID: 11280924
[TBL] [Abstract][Full Text] [Related]
20. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer.
Leonard DG; Travis LB; Addya K; Dores GM; Holowaty EJ; Bergfeldt K; Malkin D; Kohler BA; Lynch CF; Wiklund T; Stovall M; Hall P; Pukkala E; Slater DJ; Felix CA
Clin Cancer Res; 2002 May; 8(5):973-85. PubMed ID: 12006509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
